Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

746 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting the Siglec-sialic acid axis promotes antitumor immune responses in preclinical models of glioblastoma.
Schmassmann P, Roux J, Buck A, Tatari N, Hogan S, Wang J, Rodrigues Mantuano N, Wieboldt R, Lee S, Snijder B, Kaymak D, Martins TA, Ritz MF, Shekarian T, McDaid M, Weller M, Weiss T, Läubli H, Hutter G. Schmassmann P, et al. Among authors: hogan s. Sci Transl Med. 2023 Jul 19;15(705):eadf5302. doi: 10.1126/scitranslmed.adf5302. Epub 2023 Jul 19. Sci Transl Med. 2023. PMID: 37467314
Immunotherapy of glioblastoma explants induces interferon-γ responses and spatial immune cell rearrangements in tumor center, but not periphery.
Shekarian T, Zinner CP, Bartoszek EM, Duchemin W, Wachnowicz AT, Hogan S, Etter MM, Flammer J, Paganetti C, Martins TA, Schmassmann P, Zanganeh S, Le Goff F, Muraro MG, Ritz MF, Phillips D, Bhate SS, Barlow GL, Nolan GP, Schürch CM, Hutter G. Shekarian T, et al. Among authors: hogan s. Sci Adv. 2022 Jul;8(26):eabn9440. doi: 10.1126/sciadv.abn9440. Epub 2022 Jul 1. Sci Adv. 2022. PMID: 35776791 Free PMC article.
Severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration: a prospective cross-sectional study.
Etter MM, Martins TA, Kulsvehagen L, Pössnecker E, Duchemin W, Hogan S, Sanabria-Diaz G, Müller J, Chiappini A, Rychen J, Eberhard N, Guzman R, Mariani L, Melie-Garcia L, Keller E, Jelcic I, Pargger H, Siegemund M, Kuhle J, Oechtering J, Eich C, Tzankov A, Matter MS, Uzun S, Yaldizli Ö, Lieb JM, Psychogios MN, Leuzinger K, Hirsch HH, Granziera C, Pröbstel AK, Hutter G. Etter MM, et al. Among authors: hogan s. Nat Commun. 2022 Nov 9;13(1):6777. doi: 10.1038/s41467-022-34068-0. Nat Commun. 2022. PMID: 36351919 Free PMC article.
Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state.
Cerezo-Wallis D, Contreras-Alcalde M, Troulé K, Catena X, Mucientes C, Calvo TG, Cañón E, Tejedo C, Pennacchi PC, Hogan S, Kölblinger P, Tejero H, Chen AX, Ibarz N, Graña-Castro O, Martinez L, Muñoz J, Ortiz-Romero P, Rodriguez-Peralto JL, Gómez-López G, Al-Shahrour F, Rabadán R, Levesque MP, Olmeda D, Soengas MS. Cerezo-Wallis D, et al. Among authors: hogan s. Nat Med. 2020 Dec;26(12):1865-1877. doi: 10.1038/s41591-020-1073-3. Epub 2020 Oct 19. Nat Med. 2020. PMID: 33077955
PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors.
Gabryś HS, Basler L, Burgermeister S, Hogan S, Ahmadsei M, Pavic M, Bogowicz M, Vuong D, Tanadini-Lang S, Förster R, Kudura K, Huellner M, Dummer R, Levesque MP, Guckenberger M. Gabryś HS, et al. Among authors: hogan s. Front Oncol. 2022 Nov 24;12:977822. doi: 10.3389/fonc.2022.977822. eCollection 2022. Front Oncol. 2022. PMID: 36505821 Free PMC article.
Improved Survival Prediction by Combining Radiological Imaging and S-100B Levels Into a Multivariate Model in Metastatic Melanoma Patients Treated With Immune Checkpoint Inhibition.
Burgermeister S, Gabryś HS, Basler L, Hogan SA, Pavic M, Bogowicz M, Martínez Gómez JM, Vuong D, Tanadini-Lang S, Foerster R, Huellner MW, Dummer R, Levesque MP, Guckenberger M. Burgermeister S, et al. Among authors: hogan sa. Front Oncol. 2022 Apr 14;12:830627. doi: 10.3389/fonc.2022.830627. eCollection 2022. Front Oncol. 2022. PMID: 35494048 Free PMC article.
Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy.
Zila N, Eichhoff OM, Steiner I, Mohr T, Bileck A, Cheng PF, Leitner A, Gillet L, Sajic T, Goetze S, Friedrich B, Bortel P, Strobl J, Reitermaier R, Hogan SA, Martínez Gómez JM, Staeger R, Tuchmann F, Peters S, Stary G, Kuttke M, Elbe-Bürger A, Hoeller C, Kunstfeld R, Weninger W, Wollscheid B, Dummer R, French LE, Gerner C, Aebersold R, Levesque MP, Paulitschke V. Zila N, et al. Among authors: hogan sa. Clin Cancer Res. 2024 Jan 5;30(1):159-175. doi: 10.1158/1078-0432.CCR-23-0562. Clin Cancer Res. 2024. PMID: 37861398
Melanoma Immunotherapy: Next-Generation Biomarkers.
Hogan SA, Levesque MP, Cheng PF. Hogan SA, et al. Front Oncol. 2018 May 29;8:178. doi: 10.3389/fonc.2018.00178. eCollection 2018. Front Oncol. 2018. PMID: 29896449 Free PMC article. Review.
Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer.
Hurkmans DP, Verdegaal EME, Hogan SA, de Wijn R, Hovestad L, van den Heuvel DMA, Ruijtenbeek R, Welters MJP, van Brakel M, Basak EA, Pinedo HM, Lamers CHJ, van de Werken HJG, Groten JP, Debets R, Levesque MP, Dummer R, Kapiteijn E, Mathijssen RHJ, Aerts JGJV, van der Burg SH. Hurkmans DP, et al. J Immunother Cancer. 2020 Dec;8(2):e001607. doi: 10.1136/jitc-2020-001607. J Immunother Cancer. 2020. PMID: 33427690 Free PMC article.
746 results